Finafloxacin
- Generic Name
- Finafloxacin
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H19FN4O4
- CAS Number
- 209342-40-5
- Unique Ingredient Identifier
- D26OSN9Q4R
- Background
Finafloxacin is a fluoroquinolone antibiotic indicated in the treatment of acute otitis externa (swimmer's ear) caused by the bacteria Pseudomonas aeruginosa and Staphylococcus aureus. Finafloxacin is marketed by Novartis under the brand Xtoro™, and was approved by the FDA in December 2014.
- Indication
Finafloxacin is indicated for the treatment of acute otitis externa (AOE) with or without an otowick, caused by susceptible strains of Pseudomonas aeruginosa and Staphylococcus aureus in patients age 1 year and older.
- Associated Conditions
- Acute Otitis Externa
- Associated Therapies
- -
Finafloxacin 300 mg Twice a Day (b.i.d.) Versus Ciprofloxacin 250 mg Twice a Day (b.i.d) in Patients With Lower Uncomplicated UTI (uUTI)
- Conditions
- Interventions
- First Posted Date
- 2008-07-28
- Last Posted Date
- 2009-06-11
- Lead Sponsor
- MerLion Pharmaceuticals GmbH
- Target Recruit Count
- 36
- Registration Number
- NCT00722735
- Locations
- 🇸🇬
National University Hospital, Singapore, Singapore
🇩🇪Medical practice, Dr. J. Hein (Principal Study Investigator), Marburg, Germany
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.